beta amyloid

Eli Lilly & Co. (NYSE: LLY) planned to go back to the drawing board with its new experimental Alzheimer’s drug, according Bloomberg. The drug, solanezumab, which was not successful with advanced Alzheimer’s patients, will be tested in patients who show signs of early stages of the disease...